Quantcast
Last updated on April 23, 2014 at 15:23 EDT

Latest VX-809 Stories

2013-12-03 12:26:52

BETHESDA, Md., Dec. 3, 2013 /PRNewswire-USNewswire/ -- U.S. Senator Michael Bennet (D-Colo.) received the Cystic Fibrosis Foundation's Breath of Life Legislator Award for his work to help improve the health and quality of life for people with cystic fibrosis. The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis, a fatal genetic disease that affects 30,000 children and adults in the United States, and 70,000 people worldwide. "Senator...

2013-04-19 16:23:29

BETHESDA, Md., April 19, 2013 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco(TM) in combination with another potential CF therapy, VX-661. The results showed a significant improvement in lung function in people with two copies of the most common CF mutation, Delta F508, who took the combination...

2013-03-26 12:29:46

Calling on provincial governments to ensure CF patients receive equitable access to KALYDECO(TM) TORONTO, March 26, 2013 /CNW/ - As part of the Common Drug Review process, the Canadian Drug Expert Committee (CDEC) has recommended that the drug KALYDECO(TM) (ivacaftor) be listed on the formulary listing of publicly funded drug plans for the treatment of cystic fibrosis in patients age six years and older who have the G551D mutation in the Cystic Fibrosis Transmembrane conductance...

2012-10-29 12:07:01

Scientists at the Hospital for Sick Children in Toronto have established that a drug recently approved by the U.S. Food and Drug Administration to treat a rare form of cystic fibrosis works in an unconventional way. Their results reveal new possibilities for treating various forms of cystic fibrosis. Cystic fibrosis is an inherited disease afflicting about 70,000 people around the world. Cystic fibrosis patients carry a defective gene that disables or destroys its protein product, which...